glp 1 toxicity GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits glp-1 liver toxicity Current status

10.1111/1751-7915.12015 89 MorelM.NgadinA

Monotherapy In the LEAD-3 trial, both doses of liraglutide as monotherapy demonstrated significant improvements in glycemic control in comparison with glimepiride ( Table 19 - 5 )

Despite its strengths as a well-designed human intervention study, the follow-up period was relatively short, limiting conclusions regarding durability of glycemic improvements, long-term insulin resistance trajectories, or effects on clinically meaningful outcomes such as diabetes progression, medication requirements, or cardiovascular risk

I started using it in August 2025 because of diabetes problems, because I was gaining a lot of weight, she explained